Respiratory syncytial virus vaccines

Kathryn Dzintars, Pharm.D., BCPS

VACCINE TYPE

  • Abrysvo is a bivalent respiratory syncytial virus (RSV) prefusion F vaccine and is indicated for:
    • Active immunization of pregnant individuals from 32 to 36 weeks gestation for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth through 6 months of age.
    • Active immunization to prevent LRTD caused by RSV in individuals 60 years of age and older.
    • Supplied as a vial of lyophilized antigen component with a prefilled sterile water syringe for diluent.
  • Arexvy is an adjuvanted RSV vaccine indicated for active immunization to prevent LRTD caused by respiratory syncytial virus (RSV; subtypes A and B) in individuals 60 and older.
    • Supplied as a single-dose vial of lyophilized antigen (RSVPreF3) with an accompanying adjuvant (AS01E) suspension for reconstitution.
  • mResvia is an mRNA vaccine containing nucleoside-modified mRNA encoding the RSV-F glycoprotein stabilized in the prefusion conformation indicated for the prevention of LRTD caused by RSV in individuals 60 and older
    • Supplied as a single-dose prefilled syringe

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 8, 2024